U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07700056) titled 'A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)' on July 07.
Brief Summary: The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
Study Start Date: Aug. 14
Study Type: INTERVENTIONAL
Condition:
Chronic Pruritus of Unknown Origin
Intervention:
DRUG: Remibrutinib
Oral administration of remibrutinib
DRUG: Placebo
Oral administration of matching placebo.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Nov...